Cargando…

Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma

BACKGROUND: Early recurrence after surgical resection is a hallmark of poor prognosis in hepatocellular carcinoma (HCC). To determine the proteomic background of early recurrence of HCC, we focused on apoptosis-related proteins. METHODS: Surgically resected tumor tissues were obtained from 80 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Morofuji, Noriaki, Ojima, Hidenori, Hiraoka, Nobuyoshi, Okusaka, Takuji, Esaki, Minoru, Nara, Satoshi, Shimada, Kazuaki, Kishi, Yoshiro, Kondo, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078925/
https://www.ncbi.nlm.nih.gov/pubmed/27799868
http://dx.doi.org/10.1186/s12014-016-9130-0
_version_ 1782462479481176064
author Morofuji, Noriaki
Ojima, Hidenori
Hiraoka, Nobuyoshi
Okusaka, Takuji
Esaki, Minoru
Nara, Satoshi
Shimada, Kazuaki
Kishi, Yoshiro
Kondo, Tadashi
author_facet Morofuji, Noriaki
Ojima, Hidenori
Hiraoka, Nobuyoshi
Okusaka, Takuji
Esaki, Minoru
Nara, Satoshi
Shimada, Kazuaki
Kishi, Yoshiro
Kondo, Tadashi
author_sort Morofuji, Noriaki
collection PubMed
description BACKGROUND: Early recurrence after surgical resection is a hallmark of poor prognosis in hepatocellular carcinoma (HCC). To determine the proteomic background of early recurrence of HCC, we focused on apoptosis-related proteins. METHODS: Surgically resected tumor tissues were obtained from 80 patients, including HCC tumor tissues, non-tumor tissues, and normal liver tissues. These samples were grouped in the discovery and validation sample sets. The expression level of 192 apoptosis-related proteins was monitored using 247 commercially available antibodies and western blotting. The intensity of protein bands was compared between the tumor and non-tumor tissues as well as between the patients who had recurrence within 2 years after surgery and those who did not. RESULTS: In the first screening, we used pooled samples. The intensity of 53 protein bands detected by 37 unique antibodies was higher in tumor tissues compared with normal liver tissues, especially tumor tissues from patients who had recurrence within 2 years after surgery. In the second screening, we examined individual samples used to make the pooled samples. Among the selected bands and antibodies, the intensity of 18 protein bands detected by 11 antibodies was higher in tumor tissues compared with that in normal tissues, especially tumor tissues from the patients with early recurrence after surgery. For the third screening, we examined the samples from newly enrolled patients using these 11 antibodies. Eighteen protein bands detected by six antibodies were selected by using the same criteria. The corresponding antigens included ERK1, PKG, Apaf1, BclX, phosphorylated c-abl, and PIASx1/2. CONCLUSIONS: We screened 192 apoptosis-related proteins using specific antibodies and western blotting. We identified 6 apoptosis-related proteins associated with carcinogenesis and early recurrence in HCC. The biological and clinical significance of the identified proteins are worth further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12014-016-9130-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5078925
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50789252016-10-31 Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma Morofuji, Noriaki Ojima, Hidenori Hiraoka, Nobuyoshi Okusaka, Takuji Esaki, Minoru Nara, Satoshi Shimada, Kazuaki Kishi, Yoshiro Kondo, Tadashi Clin Proteomics Research BACKGROUND: Early recurrence after surgical resection is a hallmark of poor prognosis in hepatocellular carcinoma (HCC). To determine the proteomic background of early recurrence of HCC, we focused on apoptosis-related proteins. METHODS: Surgically resected tumor tissues were obtained from 80 patients, including HCC tumor tissues, non-tumor tissues, and normal liver tissues. These samples were grouped in the discovery and validation sample sets. The expression level of 192 apoptosis-related proteins was monitored using 247 commercially available antibodies and western blotting. The intensity of protein bands was compared between the tumor and non-tumor tissues as well as between the patients who had recurrence within 2 years after surgery and those who did not. RESULTS: In the first screening, we used pooled samples. The intensity of 53 protein bands detected by 37 unique antibodies was higher in tumor tissues compared with normal liver tissues, especially tumor tissues from patients who had recurrence within 2 years after surgery. In the second screening, we examined individual samples used to make the pooled samples. Among the selected bands and antibodies, the intensity of 18 protein bands detected by 11 antibodies was higher in tumor tissues compared with that in normal tissues, especially tumor tissues from the patients with early recurrence after surgery. For the third screening, we examined the samples from newly enrolled patients using these 11 antibodies. Eighteen protein bands detected by six antibodies were selected by using the same criteria. The corresponding antigens included ERK1, PKG, Apaf1, BclX, phosphorylated c-abl, and PIASx1/2. CONCLUSIONS: We screened 192 apoptosis-related proteins using specific antibodies and western blotting. We identified 6 apoptosis-related proteins associated with carcinogenesis and early recurrence in HCC. The biological and clinical significance of the identified proteins are worth further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12014-016-9130-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-24 /pmc/articles/PMC5078925/ /pubmed/27799868 http://dx.doi.org/10.1186/s12014-016-9130-0 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Morofuji, Noriaki
Ojima, Hidenori
Hiraoka, Nobuyoshi
Okusaka, Takuji
Esaki, Minoru
Nara, Satoshi
Shimada, Kazuaki
Kishi, Yoshiro
Kondo, Tadashi
Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma
title Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma
title_full Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma
title_fullStr Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma
title_full_unstemmed Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma
title_short Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma
title_sort antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078925/
https://www.ncbi.nlm.nih.gov/pubmed/27799868
http://dx.doi.org/10.1186/s12014-016-9130-0
work_keys_str_mv AT morofujinoriaki antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma
AT ojimahidenori antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma
AT hiraokanobuyoshi antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma
AT okusakatakuji antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma
AT esakiminoru antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma
AT narasatoshi antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma
AT shimadakazuaki antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma
AT kishiyoshiro antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma
AT kondotadashi antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma